Apogee Therapeutics, Inc. (APGE) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Apogee Therapeutics, Inc. (APGE) Earnings Overview
As of November 14, 2026, Apogee Therapeutics, Inc. (APGE) reported trailing twelve-month net income of -$256M. The company earned $-4.22 per diluted share over the past four quarters.
Looking at the long-term picture, APGE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$40M in fiscal 2022.
Apogee Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REGN ($4.82B net income, 31.4% margin), RXRX (-$476M net income, -863.4% margin), ARQT ($30M net income, -4.3% margin), APGE has comparable earnings metrics. Compare APGE vs REGN →
APGE Earnings vs Peers
Earnings metrics vs comparable public companies
APGE Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$256M | -40.5% | -$286M | $-4.22 | - | - |
| 2024 | -$182M | -116.9% | -$217M | $-3.30 | - | - |
| 2023 | -$84M | -111.1% | -$93M | $-1.66 | - | - |
| 2022 | -$40M | - | -$31M | $-0.79 | - | - |
Download Data
Export APGE earnings history in CSV or JSON format
Free sign-in required to download data
APGE Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
APGE — Frequently Asked Questions
Quick answers to the most common questions about buying APGE stock.
What is APGE earnings per share (EPS)?
APGE trailing twelve-month (TTM) diluted EPS is $-4.22, reflecting N/A year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Apogee Therapeutics, Inc.'s net income?
Apogee Therapeutics, Inc. (APGE) trailing twelve-month net income is $-256M as of 2025. Earnings declined N/A year-over-year.
Is APGE profitable?
APGE is not currently profitable on a TTM basis, reporting a net loss of $-256M. Net margin is N/A. Investors should monitor for a return to profitability.
What is APGE's earnings growth rate?
APGE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are APGE's profit margins?
Apogee Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is APGE growing earnings?
APGE TTM EPS: $-4.22. Net income: $-256M. YoY earnings change: N/A.
What was APGE's best earnings year?
Apogee Therapeutics, Inc.'s highest annual net income on record is $-40M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were APGE's earnings last quarter?
APGE's most recent reported quarter was Q2 2026. Net income was $-86M with diluted EPS of $-1.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.